Connected drug delivery products (devices with attached / incorporated capability that includes connectivity to wider digital services) continue to be a driving force in medical devices.

In this whitepaper, Max Middleton explores the key elements that pharmaceutical companies should consider before embarking on the development and launch of a digitally enabled drug delivery device. Our insights are based on hard-won experience and focus on how companies need to adopt a new way of thinking about their users, their product and their project risks.

To receive a copy of the whitepaper, please complete the form below.

Download the whitepaper

Max Middleton

Max leads Cambridge Consultants' Product Design Engineering group and has over 15 years experience in consumer, industrial and medical product development.